prostate cancer
Conditions
Sponsors
Department of Urology, Shanghai Changhai Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Men aged 18 to 75 years; (2) Men with a diagnosis of prostate cancer confirmed by biopsy results; (3) Men with oligometastases (including lesions of the bone, or lymph nodes superior to the level of renal artery; number of lesions less than 5) detected by ECT, MRI or 68Ga PSMA PET/CT; (4) ECOG 0-1; (5) The participant is well-informed of the current treatment options and the design of this trial; he is willing and able to give informed consent for participation in the study.
Exclusion criteria
Exclusion criteria: 1. Prior exposure to any treatment for prostate cancer, including radiotherapy, chemotherapy, hormone therapy, focal therapy, etc.; 2. Prior transurethral enucleation or resection of the prostate; 3. Patients who took any abdominal surgery in the past 3 months; 4. Patients who received transrectal prostate biopsy in the past 2 weeks; 5. Sustained use of anticoagulation and antiplatelet drugs; 6. Patients who are having other malignancies or an acute/severe infection; 7. Patients who are complicated by other severe systemic diseases which, in the judgment of the investigators, are likely to interfere with the treatment, assessment or compliance associated with this trial; patients who are not suitable for general anesthesia; 8. Patients who have contradictions to radiation therapy or surgery; 9. Participation in other trials which are ongoing or have been completed within 3 months; 10. Patients who are not willing to take robotic-assisted laparoscopic prostatectomy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Early/late complications related to radiotherapy, perioperative complications related to surgery (operation time, intraoperative bleeding volume, conversion rate, intraoperative radiotherapy area fibrosis, perioperative complications, etc.); | — |
Secondary
| Measure | Time frame |
|---|---|
| Positive rate of incision margin, no recurrence time of Biochemistry after operation, urine control after operation, recovery rate of sexual function after operation, quality of life scale, OS, endocrine adverse reactions;Adverse events; | — |
Countries
China
Contacts
Public ContactShancheng Ren
Department of Urology, Shanghai Changhai Hospital
Outcome results
None listed